Table 2. Meta-analysis of the associations between XPF polymorphisms and cancer risk under the XP recessive genetic model.
| Variables | No. of | Cases/Controls | Homozygous model | Recessive model | Powerb | ||||||
| studies | OR (95%CI) | P | P het a | I2 | OR (95%CI) | P | P het a | I2 | |||
| rs1800067 (Arg415Gln) | AA vs. GG | AA vs. (AG + GG) | |||||||||
| All | 23 | 14632/15545 | 1.21 (0.73–1.99) | 0.467 | 0.020 | 45.2 | 1.20 (0.73–1.98) | 0.466 | 0.022 | 44.6 | 0.981 |
| Cancer type | |||||||||||
| Breast | 9 | 5893/6106 | 2.27 (0.81–6.35) | 0.119 | 0.040 | 54.6 | 2.26 (0.81–6.29) | 0.118 | 0.041 | 54.1 | 0.422 |
| Colorectal | 4 | 1501/1494 | 0.51 (0.06–4.25) | 0.535 | 0.073 | 68.8 | 0.51 (0.06–4.16) | 0.532 | 0.076 | 68.2 | 0.679 |
| Head neck | 3 | 1541/1946 | 1.47 (0.42–5.18) | 0.551 | 0.240 | 29.9 | 1.47 (0.41–5.23) | 0.550 | 0.238 | 30.4 | 0.651 |
| Others | 7 | 5697/5999 | 0.84 (0.44–1.63) | 0.617 | 0.222 | 28.4 | 0.85 (0.44–1.64) | 0.629 | 0.226 | 27.8 | 0.930 |
| Lung | 2 | 2633/2918 | 0.63 (0.32–1.25) | 0.185 | 0.817 | 0 | 0.95 (0.56–1.61) | 0.841 | 0.092 | 64.8 | 0.891 |
| Prostate | 2 | 1365/1300 | 2.57 (0.91–7.23) | 0.074 | / | / | 0.95 (0.77–1.17) | 0.607 | 0.482 | 0 | 0.579 |
| Brain | 1 | 526/471 | 0.70 (0.16–3.15) | 0.642 | / | / | 1.30 (0.92–1.84) | 0.134 | / | / | 0.193 |
| Endometrial | 1 | 703/714 | 0.63 (0.15–2.64) | 0.524 | / | / | 1.22 (0.91–1.65) | 0.184 | / | / | 0.266 |
| Pancreatic | 1 | 470/596 | 0.13 (0.01–2.42) | 0.172 | / | / | 0.60 (0.43–0.84) | 0.003 | / | / | / |
| Ethnicity | |||||||||||
| Caucasian | 17 | 10342/11082 | 1.46 (0.83–2.54) | 0.186 | 0.043 | 43.1 | 1.45 (0.83–2.53) | 0.192 | 0.043 | 43.1 | 0.829 |
| African American | 3 | 954/829 | 2.61(0.11–64.2) | 0.557 | / | / | 2.67 (0.11–65.67) | 0.548 | / | / | / |
| Latino | 1 | 113/299 | 0.92(0.04–22.6) | 0.956 | / | / | 0.88 (0.04–21.68) | 0.936 | / | / | / |
| Mixed | 2 | 3223/3335 | 0.42 (0.12–1.50) | 0.182 | 0.192 | 41.2 | 0.43 (0.12–1.57) | 0.201 | 0.186 | 42.9 | 0.645 |
| Source of controls | |||||||||||
| PB | 12 | 8395/9033 | 1.13 (0.56–2.28) | 0.726 | 0.079 | 41.9 | 1.13 (0.56–2.26) | 0.740 | 0.078 | 42.0 | 0.945 |
| HB | 9 | 3412/3536 | 1.71 (0.66–4.43) | 0.268 | 0.062 | 50.0 | 1.71 (0.66–4.40) | 0.268 | 0.063 | 49.7 | 0.639 |
| PB/HB | 1 | 2520/2619 | 0.62 (0.31–1.24) | 0.179 | / | / | 0.64 (0.32–1.28) | 0.210 | / | / | 0.570 |
| Sample size | |||||||||||
| <500 | 12 | 2915/3678 | 1.99 (0.72–5.48) | 0.181 | 0.164 | 33.1 | 1.98 (0.72–5.43) | 0.182 | 0.168 | 32.6 | 0.781 |
| 500–1000 | 5 | 3527/3643 | 0.56 (0.23–1.36) | 0.199 | 0.453 | 0.0 | 0.54 (0.22–1.33) | 0.181 | 0.461 | 0.0 | 0.466 |
| >1000 | 6 | 8190/8224 | 1.23 (0.60–2.51) | 0.566 | 0.016 | 64.1 | 1.24 (0.62–2.50) | 0.545 | 0.019 | 63.1 | 0.731 |
| rs1799801 (Ser835Ser) | CC vs. TT | CC vs. (CT + TT) | |||||||||
| All | 11 | 5979/6633 | 0.91 (0.79–1.04) | 0.166 | 0.783 | 0.0 | 0.89 (0.78–1.01) | 0.080 | 0.764 | 0.0 | 1 |
| Cancer type | |||||||||||
| Prostate | 3 | 1656/1623 | 1.09 (0.82–1.45) | 0.554 | 0.643 | 0.0 | 1.09 (0.83–1.43) | 0.540 | 0.705 | 0.0 | 0.994 |
| Bladder | 3 | 1529/1482 | 0.88 (0.68–1.13) | 0.305 | 0.790 | 0.0 | 0.85 (0.66–1.08) | 0.179 | 0.793 | 0.0 | 0.989 |
| Breast | 2 | 1449/2249 | 0.83 (0.63–1.08) | 0.155 | 0.219 | 33.9 | 0.85 (0.65–1.09) | 0.200 | 0.297 | 8.2 | 0.989 |
| Others | 3 | 1345/1279 | 0.88 (0.66–1.19) | 0.412 | 0.512 | 0.0 | 0.81 (0.61–1.08) | 0.157 | 0.458 | 0.0 | 0.959 |
| Melanoma | 1 | 117/111 | 0.84 (0.52–1.34) | 0.462 | / | / | 1.31 (1.01–1.69) | 0.041 | / | / | 0.298 |
| Lung | 1 | 506/441 | 1.72 (0.54–5.50) | 0.363 | / | / | 1.39 (0.81–2.39) | 0.231 | / | / | 0.314 |
| Endometrial | 1 | 722/727 | 0.85 (0.57–1.26) | 0.417 | / | / | 1.01 (0.83–1.25) | 0.896 | / | / | 0.986 |
| Ethnicity | |||||||||||
| Caucasian | 6 | 4845/5556 | 0.88 (0.76–1.02) | 0.087 | 0.792 | 0.0 | 0.87 (0.76–1.00) | 0.049 | 0.723 | 0.0 | 1 |
| African American | 2 | 397/380 | 1.70 (0.64–4.51) | 0.285 | 0.992 | 0.0 | 1.62 (0.61–4.27) | 0.331 | 0.986 | 0.0 | 0.444 |
| Asian | 3 | 737/697 | 1.07 (0.67–1.71) | 0.784 | 0.408 | 0.0 | 0.99 (0.62–1.57) | 0.963 | 0.374 | 0.0 | 0.968 |
| Source of controls | |||||||||||
| PB | 6 | 3812/4514 | 0.89 (0.76–1.06) | 0.185 | 0.595 | 0.0 | 0.88 (0.75–1.04) | 0.131 | 0.541 | 0.0 | 1 |
| HB | 5 | 2167/2119 | 0.94 (0.74–1.19) | 0.598 | 0.632 | 0.0 | 0.90 (0.72–1.13) | 0.372 | 0.645 | 0.0 | 0.999 |
| Sample size | |||||||||||
| <500 | 6 | 1338/1290 | 1.12 (0.79–1.59) | 0.518 | 0.759 | 0.0 | 1.03 (0.73–1.44) | 0.877 | 0.705 | 0.0 | 0.993 |
| 500–1000 | 2 | 1228/1168 | 0.84 (0.62–1.14) | 0.274 | 0.969 | 0.0 | 0.78 (0.58–1.05) | 0.097 | 0.616 | 0.0 | 0.921 |
| >1000 | 3 | 3413/4175 | 0.88 (0.75–1.05) | 0.153 | 0.357 | 3.0 | 0.90 (0.76–1.06) | 0.185 | 0.388 | 0.0 | 1 |
| rs2020955 (Ser662Pro) | CC vs. TT | CC vs. (CT + TT) | |||||||||
| All | 5 | 2835/2670 | 1.04 (0.70–1.57) | 0.835 | 0.903 | 0.0 | 1.07 (0.72–1.60) | 0.729 | 0.897 | 0.0 | 0.968 |
| rs744154 (intron) | GG vs. CC | GG vs. (CG + CC) | |||||||||
| All | 4 | 29328/31999 | 0.98 (0.92–1.04) | 0.507 | 0.088 | 54.1 | 0.98 (0.92–1.04) | 0.547 | 0.140 | 45.2 | 1 |
Abbreviation: HB, Hospital based; PB, Population based; FB, Family based.
The results were in bold, if the 95% CI excluded 1 or P<0.05.
a
P value for heterogeneity test.
b
Statistical power to detect an OR of 1.5 (or 0.67 = 1/1.5).